Celcuity (CELC) reported second quarter 2026 results that showed a wider net loss, an update that can influence how investors evaluate the stock’s risk profile and long term development plans.

Celcuity’s latest earnings report, which showed a larger net loss, arrived as the stock posted a 1 month share price return of 13.21% but a 3 month share price decline of 32.34%. The 1 year total shareholder return of 78.42% highlights how longer term momentum has been strong despite recent volatility.

If you want to see how other healthcare focused AI and data driven companies are trading after recent updates, it can be useful to compare Celcuity with opportunities in 40 healthcare AI stocks.

The recent swing in Celcuity’s share price sits between a wider reported loss and strong 1 year gains. Are investors reassessing the underlying business, or reacting mainly to sentiment around the latest earnings update as valuation comes into focus?

Most Popular Narrative: 41.9% Undervalued

Celcuity’s most followed narrative points to a fair value of $161.09 per share compared with the last close at $93.53. This puts a spotlight on the growth assumptions behind that gap.

Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

Want to see what justifies that higher fair value for Celcuity? The narrative leans on aggressive revenue build out, improving profit margins and a premium future earnings multiple. Curious which exact assumptions pull most of the weight in this model driven view of fair value?

Result: Fair Value of $161.09 (UNDERVALUED)

However, Celcuity’s story still hinges on future trial and regulatory decisions, so any weaker than expected VIKTORIA results or approval delays could quickly challenge this bullish narrative.

Next Steps

Given the mix of optimism and concern around Celcuity, it makes sense to move quickly and review the underlying data yourself. To see how both the potential rewards and flagged risks stack up in a single place, take a close look at the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Celcuity?

If Celcuity has sharpened your interest in focused opportunities, do not stop here. The next move is comparing it with other strong, well screened candidates.

• Target potential mispricings by scanning 48 high quality undervalued stocks that align with your preferred quality and financial strength filters.
• Secure more dependable income streams by reviewing companies in the 12 dividend fortresses that match your yield and stability goals.
• Strengthen your shortlist with the 75 resilient stocks with low risk scores and focus on businesses with more resilient risk scores before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.